Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Halogenated hydrocarbon doai
Reexamination Certificate
2011-08-30
2011-08-30
Huff, Sheela J (Department: 1643)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Halogenated hydrocarbon doai
C514S741000
Reexamination Certificate
active
08008354
ABSTRACT:
Methods of identifying death receptor sensitizing compounds and methods of using death receptor sensitizing compounds are provided.
REFERENCES:
Micheau et a.. (J. Natl. Cancer Inst. 1997; 89: 783-9).
Freshney (Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., 1983, New York, p. 4).
Dermer (Bio/Technology, 1994, 12:320).
Gura (Science, v278, 1997, pp. 1041-1042).
Aoudjit, F., et al., “Matrix Attachment Regulates Fas-induced Apoptosis in Endothelial”,The Journal of Cell Biology, 152(3), (2001), 633-643.
Boise, L. H, et al., “bcl-x, abcl-2-Related Gene That Functions as a Dominant Regulator of Apoptotic Cell Death”,Cell, 74(4), (1993), 597-608.
Bradford, M. M., “A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye Binding”,Analytical Biochemistry, 72, (1976), 248-254.
Carter, B. Z., et al., “Small-molecule XIAP inhibitors derepress downstream effector caspase and induce apoptosis of acute myeloid leukemia cells”,Blood, 105(10), (2005), 4043-4050.
Frisch, S. M., “Evidence for a function of death-receptor-related, death-domain-containing proteins in anoikis”,Current Biology, 9, (1999), 1047-1049.
Hajra, K. M., et al., “Apoptosome dysfunction in human cancer”,Apoptosis, 9, (2004), 691-704.
Irmler, M., et al., “Inhibition of death receptor signal by cellular FLIP”,Nature, 388, (Jul. 1997), 190-195.
Jiang, C., et al., “Caspases as Key Executors of Methyl Selenium-induced Apoptosis (Anoikis) of DU-145 Prostate Cancer Cells”,Cancer Research, 61, (2001), 3062-3070.
Kharbanda, S., et al., “Role for Bcl-xLas an inhibitor of cytosolic cytochrome C accumulation in DNA damage-induced apoptosis”,Proc. Natl. Acad. Sci. USA, 94, (1997), 6939-6942.
Kim, Y., et al., “An Inducible Pathway for Degradation of FLIP Protein Sensitizes Tumor Cells to TRAIL-induced Apoptosis”,The Journal of Biological Chemistry, 277(25), (2002), 22320-22329.
Krueger, A., et al., “FLICE-Inhibitory Proteins: Regulators of Death Receptor-Mediated Apoptosis”,Molecular and Cellular Biology, 21(24), (2001), 8247-8254.
Montel, A. H., et al., “Fas Involvement in Cytotoxicity Mediated by Human NK Cells”,Cellular Immunology, 166, (1995), 236-246.
Montel, A. H., et al., “Fas-Mediated Cytotoxicity Remains Intact in Perforin and Granzyme B Antisense Transfectants of a Human NK-like Cell Line”,Cellular Immunology, 165(2), (1995), 312-317.
Nagane, M., et al., “The potential of TRAIL for cancer chemotherapy”,Apoptosis, 6(3), (2001), 191-197.
Pedersen, I. M., et al., “The triterpenoid CDDO induces apoptosis in refractory CLL B cells”,Blood100(8) , (2002), 2965-2972.
Perlman, H., et al., “FLICE-inhibitory Protein Expression Differentiation during Macrophage Differentiation Confers Resistance to Fas-mediatged Apoptosis”,The Journal of Experimental Medicine, 190(11), (1999), 1679-1688.
Reed, J. C., “Drug Insight: cancer therapy strategies based on restoration of endogenous cell death mechanisms”,Nature Clinical Practice Oncology, 3(7), (2006), 388.
Rosen, K., et al., “Cell Detachment Triggers p38 Mitogen-activated Protein Kinase-dependent Overexpression of Fas Ligand”,The Journal of Biological Chemistry, 277(48), (2002), 46123-46130.
Rytömaa, M., et al., “Involvement of FADD and caspase-8 signalling in detachment-induced apoptosis”,Current Biology, 9, (1999), 1043-1046.
Sayers, T. J., et al., “Molecular Mechanisms of Immune-Mediated Lysis of Murine Renal Cancer: Differential Contributions of Perforin-Dependent Versus Fas-Mediated Pathways in Lysis by NK and T Cells”,The Journal of Immunology, 161(8), (1998), 3957-3965.
Scaffidi, C., et al., “The Role of c-FLIP in Modulation of CD95-induced Apoptosis”,The Journal of Biological Chemistry274(3), (1999), 1541-1548.
Scaffidi, C., et al., “Two CD95 (APO-1/Fas) signaling pathways”,The EMBO Journal, 17(6), (1998), 1675-1687.
Schimmer, A. D., et al., “Identification of Small Molecules that sensitize Resistant Tumor Cells to Tumor Necrosis Factor-Family Death Receptors”,Cancer Research, 66(4), (2006), 2367-2375.
Schimmer, A. D., et al., “Receptor- and mitochondrial-mediated apoptosis in acute leukemia: a translational view”,Blood, 98(13), (2001), 3541-3553.
Schimmer, A. D., et al., “Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity”,Cancer Cell, 5, (2004), 25-35.
Takeda, K., et al., “Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells”,Nature Medicine, 7(1), (2001), 94-100.
Thome, M., et al., “Regulation of Lymphocyte Proliferation and Death by Flip”,Nature, 1, (Oct. 2001), 50-58.
Wang, S., et al., “TRAIL and apoptosis induction by TNF-family death receptors”,Oncogene, 22, (2003), 8628-8633.
Wood, T. E, et al., “A novel inhibitor of glucose uptake sensitizes cells to FAS-induced cell death”,Mol Cancer Ther., 7(11), (Nov. 2008), 3546-55.
Wuchter, C., et al., “In vitro susceptibility to TRAIL-induced apoptosis of acute leukemia cells in the context of TRAIL receptor gene expression and constitutive NF-kB activity”,Leukemia, 15(6), (2001), 921-928.
Zhou, Q., et al., “Target Protease Specificity of the Viral Serpin CrmA”,The Journal of Biological Chemistry, 272(12), (1997), 7797-7800.
Brothman, A. R., et al., “Abstract: Metastatic properties of the human prostatic cell line, PPC-1, in athymic nude mice”,J. Urol., 145(5):1008, (May 1991), 1 pg.
Fuchs-Young, R., et al., “Raloxifene is a tissue-selective agonist/antagonist that functions through the estrogen receptor”,Ann N Y Acad Sci., 761, (Jun. 12, 1995), 355-60.
Mediavilla, M. D., et al., “Abstract: Doses and time-dependent effects of 3′-azido-3′-deoxythymidine on T47D human breast cancer cells in vitro”,Pharmacol. Toxicol., 87(3):138-43, (Sep. 2000), 1 pg.
Place, Andrew E., et al., “The Novel Synthetic Triterpenoid, CDDO-Imidazolide, Inhibits Inflammatory Response and Tumor Growth in Vivo”,Clin. Cancer Res., 9:2798, vol. 9, (Jul. 2003), 2798-2806.
Zavaleta, C. L., et al., “Abstract: Use of avidin/biotin-liposome system for enhanced peritoneal drug delivery in an ovarian cancer model”,Int. J. Pharm., 337(1-2):316-28, Epub Jan. 14, 2007, (Jun. 2007), 1 pg.
Reed John C.
Schimmer Aaron D
Burnham Institute for Medical Research
Huff Sheela J
Schwegman Lundberg & Woessner, P.A.
LandOfFree
Death receptor sensitizing compounds and methods of use... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Death receptor sensitizing compounds and methods of use..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Death receptor sensitizing compounds and methods of use... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2773098